Protection by ebselen against cisplatin-induced nephrotoxicity: Antioxidant system

Molecular and Cellular Biochemistry

Volumn 178, Issue 1-2, 1998, Pages 127-133

  Husain, K ^a   Morris, C ^a   Whitworth, C ^a   Trammell, G L ^b   Rybak, L P ^a   Somani, S M ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT SPRINGFIELD   (United States)

Author keywords

Antioxidant enzymes; Cisplatin; Ebselen; Glutathione; Lipid peroxidation; Nephrotoxicity

Indexed keywords

ANTIOXIDANT; CATALASE; CISPLATIN; CREATININE; EBSELEN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; KIDNEY; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; PLASMA; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; AZOLES; CATALASE; CISPLATIN; CREATININE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; KIDNEY; LIPID PEROXIDES; MALE; ORGANOSELENIUM COMPOUNDS; PLATINUM; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 0031912696     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006889427520     Document Type: Article

References (50)

1. Cozzaglio L, Doci R, Colla G, Zunino F, Casciarri G, Gennari L: A feasibility study of highdose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer. Tumori 76: 590-594, 1990
2. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F: Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelialovarian cancer. Can Chemother Pharmacol 25: 355-360, 1990
3. Gandara DR, Ferez EA, Weibe V, DeGregorio MW: Cisplatin chemoprotection and rescue: Pharmacologic modulation of toxicity. Semin Oncol 18: 49-55, 1991
4. Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF: Selective protection against cisplatin induced toxicity in kidney, gut, and bone marrow by DDTC. Cancer Res 46: 2751-2755, 1986
5. Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, Gispen WH: Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53: 544-549, 1993
6. Rybak LP, Ravi R, Somani SM: Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: Antioxidant system. Fund Appl Toxicol 26: 293-300, 1995
7. Wolfgang GHI, Dominick MA, Walsh KM, Hoeschele JD, Pegg DO: Comparative nephrotoxicity of a novel platinum compound, cisplatin and carboplatin in male Wistar rats. Fundam Appl Toxicol 22: 73-79, 1994
8. Tognella S: Pharmacological interventions to reduce platinum-induced toxicity. Cancer Treat Rev 17: 139-142, 1990
9. Hidaka S, Tsurupka M, Funakoshi T, Shimada H, Kivozumi M, Kolima S: Protective effects of dithiocarbamates against renal toxicity of cisdiamminedichloroplatinum in rats. Renal Failure 16: 337-349, 1994
10. Somani SM, Ravi R, Rybak LP: Diethyldithiocarbamate protection against cisplatin nephrotoxicity, Antioxidant System. Drug Chem Toxicol 18: 151-170, 1995
11. Qazi R, Chang AY, Borch RF, Montine T, Dedon P, Loughner J, Bennett JM: Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Can Inst 80: 1486-1488, 1988
12. Walker EM Jr, Fazekas-May MA, Heard KW, Yee S, Montague D, Jones MM: Prevention of cisplatin-induced toxicity by selected dithiocarbamates. Ann Clin Lab Sci 24: 121-133, 1994
13. Markman M, D'Acquito R, Iannoti N, Kois H, Hakes T, Bajorin D, Bosl G, Reichman B, Casper E, Magill G: Phase I trial of high dose intravenous cisplatin with simultaneous intravenous sodium thiosulphate. J Can Res Clin Oncol 117: 151-155, 1991
14. Yuhas JM., Culo F: Selective inhibition of the nephrotoxicity of cisdichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Can Treat Rep 64: 57-64, 1980
15. Babu E, Gopal Krishnan VK, Sriganth INP, Gopal Krishnan R, Sakthisekaran D: Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 144: 711, 1995
16. Fontanelli R, Spatti G, Raspagliesi F, Zunino F, DiRe F: A preoperative single course of high dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol 3: 117-121, 1992
17. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O: Protective effect of reduced glutahione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drag. Chem Biol Interact 70: 89-101, 1989
18. Heyman SN, Spokes K, Egorin MJ, Epstein F: Glycine reduces early renal parenchymal uptake of cisplatin. Kidney Int 43: 1226-1228, 1993
19. Basinger MA, Jones MM, Holscher MA: L-methionine antagonism of cis-platinum-inducednephrotoxicity. Toxicol Appl Pharmacol 103: 1-15, 1990
20. Boogaard PJ, Lempers EL, Mulder GJ, Meerman JHN: 4-methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anti-tumour activity. Biochem Pharmacol 41: 1997-2003, 1991
21. Husain K, Morris C, Whitworth C, Trammell GL, Rybak LP, Somani SM: 4-methylthiobenzoic acid protection against cisplatic nephrotoxicity: Antioxidant system. Fundam Appl Toxicol 32: 278-284, 1996
22. Jones MM, Basinger MA, Holscher MA: Thioether suppression of cisplatin nephrotoxicity in the rat. Anticancer Res 11: 449-454, 1991
23. Esposito M, Viale M, Vannozi MO, Zicca A, Cadoni A, Merlo F, Gogioso L: Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis diamminedichloroplatinum (II). Toxicol Appl Pharamcol 140: 370-377, 1996
24. Esposito M, Fulco RA, Collecchi P, Zicca A, Cadoni A, Merlo F, Rosso R, Sobero A: Improved therapeutic index of cisplatin by procaine hydrochloride. J Natl Cancer Int 82: 677-684, 1990
25. Uslu R, Bonavida B: Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diammine dichloroplatinum. Cancer 77: 725-732, 1996
26. Sugihara K, Nakano S, Koda M, Tanaka K, Fukuishi N, Gemba M: Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Jpn J Pharmacol 43: 247-252, 1987
27. Hannemann J, Baumann K: Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: Different effects of antioxidants and radical scavengers. Toxicology 51: 119-132, 1988
28. McGuiness JE, Proctor P, Demopoulos H: Ameloriation of cisplatinum nephrotoxicity by orgotein (superoxide dismutase). Physiol Chem Phys 10: 269-277, 1978
29. Baldew GS, Mol JG, de-Kanter FJ, van-Barr B, de-Goeij JJ, Vermeulen NP: The mechanism of interaction between cisplatin and selenite. Biochem Pharmacol 41: 1429-1437, 1991
30. Bull JMC, Strebel F, Sunderland BA, Bulger RE, Edwards M, Siddik ZH, Newman RA: O-(β-hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis diamminedichloroplatinum (II)/ hyperthermia treatment. Cancer Res 48: 2239-2244, 1988
31. Maiorino M, Roveri A, Ursini F: Antioxidant effect of ebselen (Pz 51): Peroxidase mimetic activity on phospholipid and cholesterol hydroperoxides vs free radical scavenger activity. Arch Biochem Biophys 295: 404-409, 1992
32. Muller A, Cadenas E, Graf P, Sies H: Glutathione peroxidase like activity in vitro and antioxidant capacity of PZ51 (ebselen). Biochem Pharmacol 33: 3235-3239, 1984
33. Baldew GW, McVie JW, Vander Valk MA, Los G, DeGoeij JJM, Vermeulen NPE: Selective reduction of cis-diamminedichloroplatinum (II) nephrotoxicity by ebselen. Cancer Res 50: 7031-7036, 1990
34. McFariss W, Reed DJ: High performance liquid chromatography of thiols and disulfides: Dinitrophenol derivatives. Meth Enzymol 143: 101-109, 1987
35. Misra HP, Fridovich I: The role of Superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide-dismutase. J Biol Chem 247: 3170-3175, 1972
36. Aebi H: Catalase in vitro. Meth Enzymol 105: 121-126, 1984
37. Flohe L, Gunzler W: Assays of glutathione peroxidase. Meth Enzymol 105: 114-121, 1994
38. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animals and tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358, 1979
39. Litterst CL, Schweitzer VG: Covalent binding of platinum to renal protein from sensitive and resistant guinea pigs treated with cisplatin: Possible role in nephrotoxicity. Res Commun Chem Pathol Pharmacol 61: 35-48, 1988
40. Read SM, Northcole DH: Minimization of variation in the response to different protein of the Coomassie blue G dye-binding assay for protein. Anal Biochem 116: 53-64, 1981
41. DeWoskin RS, Riviere JE: Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna. Toxicol Appl Pharmacol 112: 182-189, 1992
42. Ravi R, Somani SM, Rybak LP: Mechanism of cisplatin ototoxicity: Antioxidant system. Pharmacol Toxicol 76: 386-394, 1995
43. Mistry P, Merazga Y, Spargo DJ, Riley PA, McBrien DCH: The effects of cisplatin on the concentration of protein thiols and glutathione in the rat kidney. Cancer Chemother Pharmacol 28: 277-282, 1991
44. Ban M, Hettich D, Huguet N: Nephrotoxicity mechanism of cisplatinum (II) diamine dichloride in mice. Toxicol Lett 71: 161-168, 1994
45. Nakano S, Gemba M: Potentiation of cisplatin-induced lipid peroxidation in kidney cortical slices by glutathione depletion. Jpn J Pharmacol 50: 87-92, 1988
46. Kameyama Y, Gemba M: Cisplatin-induced injury to calcium uptake by mitochondria in glutathione-depleted slices of rat kidney cortex. Jpn J Pharmacol 55: 174-176, 1991
47. Zhang JG, Lindup WE: Role of mitochondria in cisplatin induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 45: 2215-2222, 1993
48. Younes M, Siegers CP: Mechanistic aspects of enhanced lipid peroxidation following glutathione depletion in vivo. Chem Biol Interact 34: 257-266, 1981
49. Sharma RP: Interactions of cisplatin with cellular zinc and copper in liver and kidney tissues. Pharmacol Res Commun 17: 197-206, 1985
50. 2. Arch Biochem Biophys 212: 411-416, 1981